These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270 [TBL] [Abstract][Full Text] [Related]
25. Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis. Umare MD; Khedekar PB; Chikhale RV ChemMedChem; 2021 Oct; 16(20):3136-3148. PubMed ID: 34288519 [TBL] [Abstract][Full Text] [Related]
26. MmpL3 a potential new target for development of novel anti-tuberculosis drugs. Rayasam GV Expert Opin Ther Targets; 2014 Mar; 18(3):247-56. PubMed ID: 24325728 [TBL] [Abstract][Full Text] [Related]
27. In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. Ismail N; Omar SV; Ismail NA; Peters RPH J Microbiol Methods; 2018 Oct; 153():1-9. PubMed ID: 30165087 [TBL] [Abstract][Full Text] [Related]
28. Mycolic acids: deciphering and targeting the Achilles' heel of the tubercle bacillus. Nataraj V; Varela C; Javid A; Singh A; Besra GS; Bhatt A Mol Microbiol; 2015 Oct; 98(1):7-16. PubMed ID: 26135034 [TBL] [Abstract][Full Text] [Related]
30. Mycolic acid index susceptibility method for Mycobacterium tuberculosis. Viader-Salvadó JM; Garza-González E; Valdez-Leal R; del Bosque-Moncayo MA; Tijerina-Menchaca R; Guerrero-Olazarán M J Clin Microbiol; 2001 Jul; 39(7):2642-5. PubMed ID: 11427584 [TBL] [Abstract][Full Text] [Related]
31. Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Kaushik A; Makkar N; Pandey P; Parrish N; Singh U; Lamichhane G Antimicrob Agents Chemother; 2015 Oct; 59(10):6561-7. PubMed ID: 26259792 [TBL] [Abstract][Full Text] [Related]
32. Novel MenA Inhibitors Are Bactericidal against Berube BJ; Russell D; Castro L; Choi SR; Narayanasamy P; Parish T Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962346 [No Abstract] [Full Text] [Related]
33. Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis. Xu W; DeJesus MA; Rücker N; Engelhart CA; Wright MG; Healy C; Lin K; Wang R; Park SW; Ioerger TR; Schnappinger D; Ehrt S Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893793 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Grzegorzewicz AE; Pham H; Gundi VA; Scherman MS; North EJ; Hess T; Jones V; Gruppo V; Born SE; Korduláková J; Chavadi SS; Morisseau C; Lenaerts AJ; Lee RE; McNeil MR; Jackson M Nat Chem Biol; 2012 Feb; 8(4):334-41. PubMed ID: 22344175 [TBL] [Abstract][Full Text] [Related]
35. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Richard M; Gutiérrez AV; Viljoen A; Rodriguez-Rincon D; Roquet-Baneres F; Blaise M; Everall I; Parkhill J; Floto RA; Kremer L Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323043 [TBL] [Abstract][Full Text] [Related]
36. In Vitro Effect of DFC-2 on Mycolic Acid Biosynthesis in Kim S; Seo H; Mahmud HA; Islam MI; Kim YS; Lyu J; Nam KW; Lee BE; Lee KI; Song HY J Microbiol Biotechnol; 2017 Nov; 27(11):1932-1941. PubMed ID: 28870005 [TBL] [Abstract][Full Text] [Related]